Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052594 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3475766 in Healthy Participants
A Phase 1 study of Dyslipidemias, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT04052594 is a Phase 1 study of Dyslipidemias that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04052594, a Phase 1 study of Dyslipidemias, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the safety and tolerability of LY3475766 when given to participants with high levels of blood fat called triglycerides. It will also investigate how the body processes the study drug and the effect of the study drug on the body. Information about any side effects will be documented. This study will last up to 16 weeks for each participant.
Conditions Studied
Interventions
- DRUG LY3475766 - IV
- DRUG LY3475766 - SC
- DRUG Placebo - IV
- DRUG Placebo - SC
Study Locations (4)
California
- WCCT Global - Cypress
Florida
- Covance Clinical Research Inc - Daytona Beach
Texas
- Covance Dallas - Dallas
Wisconsin
- Covance Clinical Research Inc - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04052594
The ClinicalTrials.gov registry entry for NCT04052594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (79% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 4 interventions - of which LY3475766 - IV is the first listed.
NCT04052594 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04052594 about?
NCT04052594 is a clinical study titled "A Study of LY3475766 in Healthy Participants". This study will evaluate the safety and tolerability of LY3475766 when given to participants with high levels of blood fat called triglycerides. It will also investigate how the body processes the study drug and the effect of the study drug on the body. Information about any side effects will be doc...
What is the current status of trial NCT04052594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-09-03. Estimated completion is 2021-03-31.
What conditions does trial NCT04052594 study?
This clinical trial studies the following conditions: Dyslipidemias.
What interventions are being tested in trial NCT04052594?
The interventions under investigation include: LY3475766 - IV (DRUG), LY3475766 - SC (DRUG), Placebo - IV (DRUG), Placebo - SC (DRUG).
Who is sponsoring clinical trial NCT04052594?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04052594 being conducted?
This trial has 4 study locations across California, Florida, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
COMPLETED · Phase 1
-
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
COMPLETED · Phase 1
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
'Ai Pono Cooking Demonstrations
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.